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Abstract. A method, probably the best one, to improve anticancer drugs permeability is
structural modification on the base of “drug-likeness” fundamental concepts in the way of reducing
ionizability and polarity, reducing number of hydrogen bond donors or acceptors and increasing
lipophilicity. The present work looks forward to modify structure of major anticancer anthracyclines in
order to improve their permeability, with a final aim to increase absorption and oral bioavailability.
SmiLib v2.0 was used first to build a combinatorial library, by virtual reactions of building blocks
(from antimetabolite and/or antineoplastic drugs) with scaffold molecules (the tetracene-5,12-dione
moiety of anthracyclines). Second, ADME-Tox web-based software tool (hosted on the server of the
Ressource Parisienne en Bioinformatique Structurale) was used to mass-computation of the most
relevant physicochemical properties for “drug-likeness” and oral bioavailability for all anthracycline
virtual derivates from combinatorial library. Qualified derivates as potential drugs were tested for
genotoxicity and acute toxicity with Tox Boxes version 2.0. Sixteen from 160 derivates created with
SmiLib v2.0 were qualified as “drug-like” compounds with good oral bioavailability. In silico toxicity
tests showed that all derivates have good values for oral administration. One derivate presented a
smaller genotoxicity and much better values for acute toxicity at oral, subcutaneous and intraperitoneal
administration than any of anthracyclines. Only at intravenous administration this derivate showed
certain acute toxicity, but the aim of the study was to improve the oral bioavailability.
Keywords: anthracycline drugs, genotoxicity, oral bioavailability, LD50, permeability.
INTRODUCTION
Anthracyclines (anthracycline antibiotics) are the largest class of quinones with
tetracene-5,12-dione moiety, effective against more types of cancer than any other class of
chemotherapy agents and some of the most effective anticancer chemotherapy agents (Minotti
et al., 2004; Velíšek et al., 2007; Weiss, 1992).
However, the anthracyclines-based chemotherapy has two major disadvantages: the
low permeability (a determinant of intestinal absorption and oral bioavailability) and their
high toxicity. Permeability is a necessary process for drug’s absorption in the intestine,
passage through restrictive organ barriers (especially blood-brain barrier), penetration into
cells (reaching at intracellular therapeutic target), elimination by the liver and excretion by the
kidneys (Kerns and Di, 2008). The most important permeability mechanism for drug
discovery is passive diffusion, Mandagere et al. (2002) estimating that 95% of commercial
drugs are predominantly absorbed in the gastrointestinal tract by passive diffusion.
In the last years, computational techniques have an increase development, due to the
enormous cost to bring a drug to the market. Recent estimations have showed that typical cost
of experiments per compound started from 10 USD for computer modeling, continuing with
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400 USD for biochemical assay, and afterwards graduated increasing to 500,000,000 USD for
human clinical trial (Young, 2009).
Aiming to increase absorption and bioavailability and decrease toxicity, current work
attempts to improve anthracyclines anticancer drugs permeability by virtual structural
modification. This study takes in consideration virtual structural modification of principal
approved anthracyclines for cancer therapy: daunorubicin (DNM), doxorubicin (DOX),
epirubicin (EPI), idarubicin (IDA), valrubicin (VAL) – DNA topoisomerase IIα (TOP2A)
inhibitors.
MATERIALS AND METHODS
The research has been carried out in silico using combinatorial library software –
SmiLib v2.0 (Schüller et al., 2003) – to build a virtual library, for the derivates of the five
anthracyclines: daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin. Virtual
combinatorial library was created with the help of SmiLib v2.0, which works with three
classes of molecules: scaffold molecules (Markush structures of molecules that contain R-
groups – sites of variability), building blocks (small Markush molecules) and linkers
(connectors between scaffold molecules and building blocks). In order to reduce molecular
weight, a metric of oral bioavailability and of “drug-likeness” according to Lipinski et al.
(1997), from the beginning of this study, only tetracene-5,12-dione moiety was used as
backbone molecule for virtual derivates. Because of structural similarity of anthracyclines, it
resulted only two types of backbone molecules with tetracene-5,12-dione moiety: one
common to  DNM, DOX, EPI and VAL, and another for IDA (Fig. 1).
Fig. 1. The two types of backbone molecules with tetracene-5,12-dione moiety
For scaffold molecules there were taken in consideration two types of backbone
molecules with tetracene-5,12-dione moiety (Fig. 1) and there were imposed two possible
positions for sites of variability (R-groups: R1 and R2). Because the aim of the study was to
improve permeability, the scaffold molecules were designed based on minimal molecular
weight, assuming only one site of variability for each scaffold molecule – a total number of
four structures had resulted (Tab. 1, Fig. 2).
Table 1
Enhanced SMILES strings for scaffold molecules (SM)
No. Code Enhanced SMILES strings for SM
1 SM DDEV-R1 COc:3:c:c:c:c:4:c(=O):c:2:c(O):c:1CC(O)CC([R1])c1:c(O):c2:c(=O):c34
2 SM DDEV-R2 COc:3:c:c:c:c:4:c(=O):c:2:c(O):c:1CC(O)([R1])CC(O)c1:c(O):c2:c(=O):c34
3 SM I-R1 O=c:3:c:1:c:c:c:c:c1:c(=O):c:4:c(O):c2:c(CC(O)CC2[R1]):c(O):c34
4 SM I-R2 O=c3c1ccccc1c(=O)c4c(O)c2c(CC(O)([R1])CC2O)c(O)c34
Note: SMILES is the abbreviation for Simplified Molecular Input Line Entry System . SmiLib v2.0
mandatory requires a [R1] label for each SM with a single site of variability.
331
Fig. 2. The structure of scaffold molecules (SM). R1 and R2 marks the positions imposed to the sites of
variability [R1]
To decrease molecular weight SmiLib v2.0 concatenated scaffolds with building
blocks using a dummy (empty) linker: [A][R], where [A] is linker’s attachment site and [R] is
linker’s site of variability. Building blocks were made on the base of structural motifs most
frequently found in some antimetabolite/antineoplastic drugs (Fig. 3, Tab. 2).
Fig. 3. The structure of building blocks (BB); [A] represents the attachment sites
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Table 2
Enhanced SMILES strings for building blocks (BB)
No. Code Enhanced SMILES strings for BB BB origin / anticancer drug
category
1 BB1 O=P1(N([A])CCCl)NCCCO1 cyclophosphamide / AnAg-Alk
2 BB2 O=P1([A])NCCCO1 cyclophosphamide / AnAg-Alk
3 BB3 O=P1(N[A])NCCCO1 cyclophosphamide / AnAg-Alk
4 BB4 CNP1(=O)NCC([A])CO1 cyclophosphamide / AnAg-Alk
5 BB5 ClCCN([A])CCCl mechlorethamine / AnAg-Alk
6 BB6 ClCCN(C[A])CCCl mechlorethamine / AnAg-Alk
7 BB7 CN(CCCl)CC[A] mechlorethamine / AnAg-Alk
8 BB8 CN([A])CCCl mechlorethamine / AnAg-Alk
9 BB9 O=c:1:[nH]:c:c(N([A])CCCl):c(=O):[nH]1 uramustine / AnAg-Alk
10 BB10 O=c:1:[nH]:c:c(N[A]):c(=O):[nH]1 uramustine / AnAg-Alk
11 BB11 O=c:1:[nH]:c:c([A]):c(=O):[nH]1 uramustine / AnAg-Alk
12 BB12 O=c:1:c:c:n([A]):c(=O):[nH]1 uramustine / AnAg-Alk
13 BB13 O=c:1:c:c([A]):[nH]:c(=O):[nH]1 uramustine / AnAg-Alk
14 BB14 Nc:1:c:c:c(CC(N)C(=O)O[A]):c:c1 melphalan / AnAg-Alk
15 BB15 Nc:1:c:c:c(C([A])C(N)C(=O)O):c:c1 melphalan / AnAg-Alk
16 BB16 CN(C)c:1:c:c:c(CC(N)[A]):c:c1 melphalan / AnAg-Alk
17 BB17 ClCCN(CCCl)c:1:c:c:c([A]):c:c1 melphalan / AnAg-Alk
18 BB18 O=NN(CC[A])C(=O)NCCCl carmustine / AnAg-Alk
19 BB19 O=NN(CCCl)C(=O)NCC[A] carmustine / AnAg-Alk
20 BB20 NC(=O)N([A])N=O carmustine / AnAg-Alk
21 BB21 O=NNC(=O)N[A] carmustine / AnAg-Alk
22 BB22 O=NN([A])C(=O)NC1CCCCC1 lomustine / AnAg-Alk
23 BB23 OCC1OC(O)C(N[A])C(O)C1O streptozotocin / AnAg-Alk
23 BB24 NC1C(O)OC(C(O)[A])C(O)C1O streptozotocin / AnAg-Alk
25 BB25 CS(=O)(=O)OC[A] busulfan / AnAg-Alk
26 BB26 CS(=O)(=O)OCCC([A])COS(C)(=O)=O busulfan / AnAg-Alk
27 BB27 NC(=O)c:1:c:c:c(CNN[A]):c:c1 procarbazine / AnAg-Alk
28 BB28 S=c:1:n:c:[nH]:c:2:n:c([A]):[nH]:c12 mercaptopurine / AmAnAg-Imm
29 BB29 S=c:1:n:c:n([A]):c:2:n:c:[nH]:c12 mercaptopurine / AmAnAg-Imm
30 BB30 Nc:2:n:c(=S):c:1:[nH]:c([A]):n:c1:[nH]2 thioguanine / AmAnAg
31 BB31 S=c:1:n:c(N[A]):[nH]:c:2:n:c:[nH]:c12 thioguanine / AmAnAg
32 BB32 O=C(O)CCC(NC(=O)c:1:c:c:c(N[A]):c:c1)C(=O)O methotrexate / AmAnAg-Imm
33 BB33 O=C(O)CCC(NC(=O)C[A])C(=O)O methotrexate / AmAnAg-Imm
34 BB34 CN([A])Cc:2:c:n:c:1:n:c(N):n:c(N):c1:n2 methotrexate / AmAnAg-Imm
35 BB35 CC(NC(=O)c:1:c:c:c(N(C)C[A]):c:c1)C(=O)O methotrexate / AmAnAg-Imm
36 BB36 CCN(C)c:1:c:c:c(C(=O)NC([A])C(=O)O):c:c1 methotrexate / AmAnAg-Imm
37 BB37 Nc:2:n:c(=O):c:1:c(C[A]):c:[nH]:c1:[nH]2 pemetrexed / AmAnAg
38 BB38 Cc:2:n:c(=O):c:1:c:c(CN(C)[A]):c:c:c1:[nH]2 raltitrexed / AmAnAg
39 BB39 CC(NC(=O)c:1:c:c:c(N[A]):s1)C(=O)O raltitrexed / AmAnAg
40 BB40 O=C(O)CCC(NC(=O)[A])C(=O)O raltitrexed / AmAnAg
Note: [A] marks the attachment sites from building blocks. AnAg-Alk stands for antineoplastic agents,
alkylating. AmAnAg-Imm stands for antimetabolite antineoplastic agents, immunosuppressant. AmAnAg stands
for antimetabolite antineoplastic agents.
All the three classes of molecules (scaffold molecules, empty linker and building
blocks) were manually loaded in SmiLib v2.0 as enhanced SMILES strings in order to build
the combinatorial library of virtual derivatives. Resulted combinatorial library was tested for
“drug-likeness” and oral bioavailability with ADME-Tox web-based software tool (hosted on
the server of Ressource Parisienne en Bioinformatique Structurale, RPBS:
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http://bioserv.rpbs.jussieu.fr/). ADME-Tox web-based tool software allowed selecting tested
parameters and imposing a series of conditions for “drug-likeness” and oral bioavailability.
Tested parameters referred to molecular weight (MW), number of hydrogen donors (Drs),
number of hydrogen acceptors (Ars), number of flexible (rotatable) bonds (FB), calculated
octanol/water partition coefficient (logP) and polar surface area (PSA). For calculated
octanol/water partition coefficient it was used the method described by Wang et al. (1997,
2000). For PSA calculation, ADME-Tox web-based tool software used the method of a
topological polar surface area (Ertl et al., 2000). Based on “drug-likeness” metrics from
literature, including the Lipinski rule of fives (Lipinski et al., 1997) for oral bioavailability,
there were imposed six conditions for the virtual derivatives. The conditions represent a
combination between the most tolerant values and limits from literature for physicochemical
properties: MW (Lipinski et al., 1997), Drs (Lipinski et al., 1997; Oprea et al., 2005), Ars
(Lipinski et al., 1997), FB (Oprea et al., 2005), logP (Lipinski et al., 1997) and PSA (Palm et
al., 1997). For comparative reasons, the same conditions were imposed to all five
anthracyclines. All derivates qualified as potential drugs with a good permeability (increased
absorption and oral bioavailability) were in depth analyzed for toxicity. Tox Boxes version
2.0, web-based tool software from Pharma Algorithms, Inc., (http://pharma-
algorithms.com/webboxes/) predicted probabilities for basic toxicity endpoints of each
anthracycline and qualified derivate.
RESULTS AND DISCUSSION
The combinatorial library, created by virtual reactions of the four SM with forty BB
connected themselves by empty linkers, contains 160 virtual anthracycline derivates, saved as
SMILES strings and SD files (data not showed for unqualified derivates). SmiLib v2.0
created all the virtual derivates using the following syntax: SMno.linker1_BBno, where SMno
is the identifier (number) assigned to each SM (see Tab. 1 and Fig. 2), linker1 represents the
empty linker, and BBno comes from the identifier (number) assigned to each BB (see Tab. 2
and Fig. 3). SM identifiers and linker/building block groups were separated by “.”, linker and
building block identifiers were separated by “_”. ADME-Tox web-based tool software
calculated molecular properties of anthracyclines (Tab. 3) and qualified, using imposed
conditions, as potential drug candidates with good oral bioavailability only 16 of 160
derivatives from combinatorial library (Tab. 4).
Table 3
Molecular (physicochemical) properties of anthracyclines
Property MW Drs Ars FB logP PSA
DNM 527.3 5 11 4 0.56 185.84
DOX/EPI 543.3 6 12 5 -0.04 206.07
VAL 723.4 5 14 12 2.63 215.22
IDA 497.3 5 10 3 0.65 176.61
Note: DOX and EPI have the same SMILES strings and 2D structures; the difference between the two
anthracyclines is the spatial orientation of the hydroxyl group at the 4' carbon of the sugar.
Table 3 shows that only IDA accomplishes at least three conditions of Lipinski rule of
fives (those for MW, Drs and logP), indicating a good bioavailability according to Lipinski et
al. (1997). In addition, values for PSA over-exceed, for all anthracyclines, the limit imposed
by Palm et al. (1997). However, values of metrics from Lipinski rule of fives and PSA predict
only intestinal passive absorption and not the active transport and this is reason why
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anthracyclines have, in general, a low oral bioavailability, being not enough lipophilic to enter
the blood-stream through passive intestinal absorption in small intestine, according to Kerns
and Di (2008) considerations.
Table 4
Molecular (physicochemical) properties of qualified virtual anthracycline derivates
Property
and limit
MW
≤ 500 Da
Drs
≤ 5
Ars
≤ 10
FB
≤ 10
logP
≤5
PSA
≤ 140Å2
1.1_5 480.2 3 7 6 3.13 107.30
1.1_6 494.2 3 7 7 3.05 107.30
1.1_7 459.7 3 7 6 2.64 107.30
1.1_8 431.7 3 7 4 2.36 107.30
2.1_5 496.2 4 8 6 2.55 127.53
2.1_7 475.7 4 8 6 2.01 127.53
2.1_8 447.7 4 8 4 1.78 127.53
3.1_5 450.2 3 6 5 3.21 98.07
3.1_6 464.2 3 6 6 3.14 98.07
3.1_7 429.7 3 6 5 2.73 98.07
3.1_8 401.7 3 6 3 2.45 98.07
3.1_16 472.3 4 7 4 3.09 124.09
4.1_5 466.1 4 7 5 2.63 118.30
4.1_6 480.2 4 7 6 2.50 118.30
4.1_7 445.7 4 7 5 2.09 118.30
4.1_8 417.7 4 7 3 1.87 118.30
Table 4 indicates that all four SM were equally used in structures of qualified
derivates. In the same time, the two types of backbone molecules with tetracene-5,12-dione
moiety were equally used in resulted qualified derivates. Analyzing BB usage, it can be
observed an unequal distribution of the forty structures in resulted qualified derivates:
identifiers 5, 7 and 8 appear each of them in four structures; identifier 6 appears in three
structures; identifier 16 appears only in one new structure. Comparing Tab. 4 with Tab. 2 and
Fig. 3, it can be remarked that all BB have origin in two alkylating antineoplastic agents:
mechlorethamine and melphalan. Moreover, BB from mechlorethamine appeared in fifteen
new structures and melphalan in only one structure. All 16 derivates accomplishes at least
three of conditions of Lipinski rule of fives (those for MW, Drs and logP) and for PSA limit,
indicating a good bioavailability according to Lipinski et al. (1997) and Palm et al. (1997).
Table 5 presents Tox Boxes version 2.0 results for each qualified derivates for
genotoxicity predictions and acute toxicity (LD50). Qualified derivates with DNM, DOX, EPI
and VAL common backbone were tested against corresponding anthracyclines; qualified
derivates with IDA backbone were tested against IDA.
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Tab. 5
Genotoxicity predictions and acute toxicity for anthracyclines and qualified derivates
Codes GA
Acute toxicity on mouse
LD50 (mg/kg) Log LD50 (pLD50)
ip o iv sc ip o iv sc
DNM 1.000 5.8 100 16 22 1.96 0.71 1.53 1.39
DOX/EPI 1.000 19 210 35 66 1.46 0.41 1.19 0.91
VAL 1.000 170 590 91 210 0.64 0.09 0.90 0.53
1.1_5 1.000 20 200 19 61 1.37 0.38 1.40 0.90
1.1_6 1.000 7.6 120 11 29 1.81 0.61 1.65 1.23
1.1_7 1.000 21 190 19 57 1.34 0.38 1.39 0.91
1.1_8 1.000 28 240 17 81 1.19 0.25 1.41 0.73
2.1_5 1.000 12 140 20 53 1.61 0.56 1.39 0.97
2.1_7 0.999 27 210 16 95 1.25 0.36 1.48 0.70
2.1_8 1.000 31 200 36 95 1.16 0.34 1.09 0.67
IDA 0.999 6.5 100 18 26 1.88 0.64 1.43 1.28
3.1_5 1.000 20 220 23 76 1.35 0.30 1.29 0.77
3.1_6 1.000 9 140 13 36 1.71 0.53 1.55 1.11
3.1_7 0.999 23 220 22 69 1.28 0.30 1.28 0.79
3.1_8 1.000 41 270 34 99 0.99 0.18 1.08 0.61
3.1_16 0.987 200 780 49 430 0.38 -0.22 0.99 0.04
4.1_5 1.000 15 160 24 65 1.51 0.48 1.28 0.85
4.1_6 1.000 7.7 110 9.1 41 1.80 0.62 1.72 1.06
4.1_7 0.999 31 230 34 120 1.16 0.28 1.12 0.58
4.1_8 0.999 36 230 43 120 1.07 0.26 0.98 0.55
Note: GA represents genotoxicity (probability of positive Ames test). LD50 and pLD50 were calculated
for intraperitoneal (ip), oral (o), intravenous (iv) and subcutaneous (sc) administration. Underline values
represents the highest toxicity values.
Table 5 shows that all seven derivates with DNM, DOX, EPI and VAL common
backbone have good values for acute toxicity for oral administration. However, VAL presents
a smaller acute toxicity for all acute toxicity tests that any of other anthracyclines and
corresponding derivates does. Genotoxicity predictions were the same for DNM, DOX, EPI,
VAL and their derivates. On the other hand, the IDA’s derivate 3.1_16 presented a small
improvement of genotoxicity value. Acute toxicity predictions for 3.1_16 showed a very low
toxicity for subcutaneous and oral predictions (better than IDA and VAL). A good value has
been achieved for intraperitoneal administration of 3.1_16, also better than IDA and VAL. At
intravenous administration, 3.1_16 presents certain toxicity, being less toxic than IDA, but
having a greater value than VAL. All nine IDA’s derivates present good values for oral and
subcutaneous administration.
CONCLUSIONS
Structural modification of anthracyclines’ backbone to improve their permeability
generated a combinatorial library with 160 derivates. Sixteen derivates have shown “drug-
like” characteristics and a good oral bioavailability. All those 16 derivates are safe for oral
administration, according to computational predictions. Moreover, all IDA’s derivates present
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good values for subcutaneous administration. One of IDA’s derivates (3.1_16) shows better
values that any of the anthracyclines for oral, subcutaneous and intraperitoneal administration
and certain toxicity for intravenous administration does. In silico docking studies will be
considered for the evaluation of the new derivates binding in the active site of TOP2A
(because of their backbone molecules with tetracene-5,12-dione moiety found in
anthracyclines) or DNA binding (because of their BB origins from mechlorethamine and
melphalan).
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